Reverse Transcriptase Activity of Hepatitis B Virus (HBV) DNA Polymerase within Core Capsid: Interaction with Deoxynucleoside Triphosphates and Anti-HBV L-Deoxynucleoside Analog Triphosphates

Molecular Pharmacology

Volumn 65, Issue 2, 2004, Pages 400-406

  Lam, Wing ^a   Li, Ying ^a   Liou, Jieh Yuan ^a   Dutschman, Ginger E ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2'-DEOXYCYTIDINE 5'-TRIPHOSPHATE; ANTIVIRUS AGENT; CLEVUDINE; DEOXYCYTIDINE PHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYNUCLEOSIDE TRIPHOSPHATE; DNA DIRECTED DNA POLYMERASE; DNA POLYMERASE; ELVUCITABINE; LAMIVUDINE; NUCLEOSIDE TRIPHOSPHATE; PURINE NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL; ANTIBIOTIC RESISTANCE; ARMYWORM; ARTICLE; CELL LINE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENE MUTATION; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; METABOLISM; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS CAPSID; VIRUS NUCLEOCAPSID;

ANIMALS; ANTIVIRAL AGENTS; CAPSID; CELL LINE; DEOXYCYTOSINE NUCLEOTIDES; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; MUTATION; NUCLEOCAPSID; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SPODOPTERA;

EID: 1642498142     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.2.400     Document Type: Article

References (39)

1. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, and Cheng YC (1996) Inhibition of hepatitis B virus by a novel L-nucleoside, 2′ -fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 40:380-386.
2. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, and Brown NA (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
3. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, and Thomas HC (1989) Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591.
4. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, Tsai CH, Cheng YC, Liotta D, and Schinazi R (1992) Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′ -thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 267:13938-13942.
5. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, Bowden S Desmond P and Locarnini SA (2003) Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
6. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. Chong Y and Chu CK (2002) Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg Med Chem Lett 12:3459-3462.
8. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, and Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771-4779.
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, and Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
10. Doong SL, Tsai CH, Schinazi RF, Liotta DC, and Cheng YC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 19:8495-8499.
11. Fu L and Cheng YC (1998) Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55:1567-1572.
12. Fu L and Cheng YC (2000) Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine-and penciclovir-resistant virus. Antimicrob Agents Chemother 44:3402-3407.
13. Funk ML, Rosenberg DM, and Lok AS (2002) World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 9:52-61.
14. Hadziyannis SJ and Vassilopoulos D (2001) Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624.
15. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, and Papaioannou C (2000) Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 32:847-851.
16. Honkoop P, De Man RA, Zondervan PE, and Schalm SW (1997) Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17:103-106.
17. Kao JH and Chen DS (2002) Global control of hepatitis B virus infection. Lancet Infect Dis 2:395-403.
18. Kukhanova M, Lin ZY, Yas'co M and Cheng YC (1998) Unique inhibitory effect of 1-(2′-deoxy-2′-fluoro-beta-L-arabinofuranosyl)-5- methyluracil 5′-triphosphate on Epstein-Barr virus and human DNA polymerases. Biochem Pharmacol 55:1181-1187.
19. Ladner SK, Miller TJ, Otto MJ, and King RW (1998) The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir Chem Chemother 9:65-72.
20. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, and Wu PC (1997) Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
21. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, et al. (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
22. Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trepo C, et al. (2000) Characterization of the antiviral effect of 2′, 3′-dideoxy-2′,3′ -didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 44:111-122.
23. Le Guerhier F, Pichoud C, Jamard C, Guerret S, Chevallier M, Peyrol S, Hantz O, King I, Trepo C, Cheng YC, et al. (2001) Antiviral activity of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 45:1065-1077.
24. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, et al. (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
25. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, et al. (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119:172-180.
26. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, and Harrison TJ (1996) Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
27. Liu CJ, Kao JH, Chen PJ, Lai MY, and Chen DS (2002) Molecular epidemiology of hepatitis B viral serotypes and genotypes in Taiwan. J Biomed Sci 9:166-170.
28. Lok AS, Akarca U, and Greene S (1994) Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 91:4077-4081.
29. Ma T, Lin JS, Newton MG, Cheng YC, and Chu CK (1997) Synthesis and anti-hepatitis B virus activity of 9-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) purine nucleosides. J Med Chem 40:2750-2754.
30. Melegari M, Scaglioni PP, and Wands JR (1998) Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
31. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, et al. (2001) Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254-266.
32. Ruth JL and Cheng YC (1981) Nucleoside analogues with clinical potential in antivirus chemotherapy. The effect of several thymidine and 2′-deoxycytidine analogue 5′-triphosphates on purified human (α, β) and herpes simplex virus (types 1, 2) DNA polymerases. Mol Pharmacol 20:415-422.
33. Seifer M, Hamatake R, Bifano M, and Standring DN (1998) In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. J Virol 72:2765-2776.
34. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, and Zoulim F (2002) Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36:710-722.
35. Tyrell DLJ, Fischer K, Savani K, Tan W, and Jewell L (1993) Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy-3′ -thiacytidine, results in a rapid suppression of hepaviral DNA in sera. Clin Investig Med 16 (Suppl 4):B77.
36. Tyrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Beranek P, and Vicary C (1993) Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A
37. Xiong X, Flores C, Yang H, Toole JJ, and Gibbs CS (1998) Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
38. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, and Cheng YC (1996) Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Biochem Pharmacol 51:941-947.
39. Zhu YL, Dutschman GE, Liu SH, Bridges EG, and Cheng YC (1998) Anti-hepatitis B virus activity and metabolism of 2′,3′ -dideoxy-2′,3′-didehydro-beta-L(-)-5-fluorocytidine. Antimicrob Agents Chemother 42:1805-1810.